190 related articles for article (PubMed ID: 32653014)
1. Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy.
Marchica V; Franceschi V; Vescovini R; Storti P; Vicario E; Toscani D; Zorzoli A; Airoldi I; Dalla Palma B; Campanini N; Martella E; Mancini C; Costa F; Donofrio G; Giuliani N
J Hematol Oncol; 2020 Jul; 13(1):89. PubMed ID: 32653014
[TBL] [Abstract][Full Text] [Related]
2. Reovirus as a viable therapeutic option for the treatment of multiple myeloma.
Thirukkumaran CM; Shi ZQ; Luider J; Kopciuk K; Gao H; Bahlis N; Neri P; Pho M; Stewart D; Mansoor A; Morris DG
Clin Cancer Res; 2012 Sep; 18(18):4962-72. PubMed ID: 22761466
[TBL] [Abstract][Full Text] [Related]
3. Attenuated measles virus controls pediatric acute B-lineage lymphoblastic leukemia in NOD/SCID mice.
Lühl NC; Zirngibl F; Dorneburg C; Wei J; Dahlhaus M; Barth TF; Meyer LH; Queudeville M; Eckhoff S; Debatin KM; Beltinger C
Haematologica; 2014 Jun; 99(6):1050-61. PubMed ID: 24700491
[TBL] [Abstract][Full Text] [Related]
4. Infection and killing of multiple myeloma by adenoviruses.
Senac JS; Doronin K; Russell SJ; Jelinek DF; Greipp PR; Barry MA
Hum Gene Ther; 2010 Feb; 21(2):179-90. PubMed ID: 19788385
[TBL] [Abstract][Full Text] [Related]
5. Enhancing therapeutic efficacy of oncolytic vaccinia virus armed with Beclin-1, an autophagic Gene in leukemia and myeloma.
Lei W; Wang S; Xu N; Chen Y; Wu G; Zhang A; Chen X; Tong Y; Qian W
Biomed Pharmacother; 2020 May; 125():110030. PubMed ID: 32187960
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.
Peng KW; Dogan A; Vrana J; Liu C; Ong HT; Kumar S; Dispenzieri A; Dietz AB; Russell SJ
Am J Hematol; 2009 Jul; 84(7):401-7. PubMed ID: 19507209
[TBL] [Abstract][Full Text] [Related]
7. Advances in viral oncolytics for treatment of multiple myeloma - a focused review.
Sarwar A; Hashim L; Faisal MS; Haider MZ; Ahmed Z; Ahmed TF; Shahzad M; Ansar I; Ali S; Aslam MM; Anwer F
Expert Rev Hematol; 2021 Dec; 14(12):1071-1083. PubMed ID: 34428997
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic virotherapy for multiple myeloma.
Stief AE; McCart JA
Expert Opin Biol Ther; 2008 Apr; 8(4):463-73. PubMed ID: 18352850
[TBL] [Abstract][Full Text] [Related]
9. Transplantation of autologous bone marrow pre-loaded
Villa NY; Rahman MM; Mamola J; Sharik ME; de Matos AL; Kilbourne J; Lowe K; Daggett-Vondras J; D'Isabella J; Goras E; Chesi M; Bergsagel PL; McFadden G
Oncotarget; 2022; 13():490-504. PubMed ID: 35251496
[TBL] [Abstract][Full Text] [Related]
10. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth.
Munguia A; Ota T; Miest T; Russell SJ
Gene Ther; 2008 May; 15(10):797-806. PubMed ID: 18356812
[TBL] [Abstract][Full Text] [Related]
11. Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread.
Ayala-Breton C; Suksanpaisan L; Mader EK; Russell SJ; Peng KW
Mol Ther; 2013 Oct; 21(10):1930-7. PubMed ID: 23842448
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Virotherapy and Microenvironment in Multiple Myeloma.
Marchica V; Costa F; Donofrio G; Giuliani N
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668361
[TBL] [Abstract][Full Text] [Related]
13. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
Naik S; Nace R; Barber GN; Russell SJ
Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo.
Yarde DN; Nace RA; Russell SJ
Exp Hematol; 2013 Dec; 41(12):1038-49. PubMed ID: 24067362
[TBL] [Abstract][Full Text] [Related]
15. Systemic virotherapy for multiple myeloma.
Oliva S; Gambella M; Boccadoro M; Bringhen S
Expert Opin Biol Ther; 2017 Nov; 17(11):1375-1387. PubMed ID: 28796556
[TBL] [Abstract][Full Text] [Related]
16. A CRISPR/Cas9 Generated Bovine CD46-knockout Cell Line-A Tool to Elucidate the Adaptability of Bovine Viral Diarrhea Viruses (BVDV).
Szillat KP; Koethe S; Wernike K; Höper D; Beer M
Viruses; 2020 Aug; 12(8):. PubMed ID: 32781607
[TBL] [Abstract][Full Text] [Related]
17. MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.
Muñoz-Alía MÁ; Nace RA; Tischer A; Zhang L; Bah ES; Auton M; Russell SJ
PLoS Pathog; 2021 Feb; 17(2):e1009283. PubMed ID: 33534834
[TBL] [Abstract][Full Text] [Related]
18. Different impact of bovine complement regulatory protein 46 (CD46
Leveringhaus E; Cagatay GN; Hardt J; Becher P; Postel A
Emerg Microbes Infect; 2022 Dec; 11(1):60-72. PubMed ID: 34839792
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.
Packiriswamy N; Upreti D; Zhou Y; Khan R; Miller A; Diaz RM; Rooney CM; Dispenzieri A; Peng KW; Russell SJ
Leukemia; 2020 Dec; 34(12):3310-3322. PubMed ID: 32327728
[TBL] [Abstract][Full Text] [Related]
20. Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.
Müller LME; Migneco G; Scott GB; Down J; King S; Askar B; Jennings V; Oyajobi B; Scott K; West E; Ralph C; Samson A; Ilett EJ; Muthana M; Coffey M; Melcher A; Parrish C; Cook G; Lawson M; Errington-Mais F
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]